How And Why Genzyme And Alnylam Expanded Their Alliance
Executive Summary
Genzyme’s decision to deepen its alliance with Alnylam plays to the strategic needs of both parties and to their complementary strengths. The agreement also was helped by the companies’ physical proximity and by a high-level conversation between Maraganore and Viehbacher sealed the deal.
You may also be interested in...
Biopharma Dealmaking Quarterly Statistics, Q1 2014
Biopharma financing totaled $9.8 billion, a 53% increase over Q4 2013. Twenty-two M&As were completed with a combined potential value reaching $31.3 billion, and there were 103 biopharma alliances totaling $1.9 billion in potential pre-commercialization value, down 30% from the previous quarter.
Financings Of The Fortnight And The Never-Ending Venture Round
While not as high-profile as some other venture raises over the last year, Novimmune has pulled in CHF 200.5 million in Series B financing over 16 years. Plus, news on raises by Pronutria, Melinta, Argos and Arrowhead.
Alnylam’s Comeback: RNAi Developer Partners With Sanofi/Genzyme
Sanofi will take a 12% stake in Alnylam for $700 million in a transformative deal that revalidates the biotech’s RNAi technology platform after the company lost important big pharma partners three years ago. The announcement Jan. 13 kicked off the opening of the JP Morgan Healthcare conference.